

Supplementary Table 5. Hemocompatibility-associated adverse events compared between HeartMate II vs. HVAD devices

Adverse event	Total (n = 50)	HeartMate II (n = 17)	HVAD (n = 33)	<i>p</i> value
Suspected or confirmed pump thrombosis				
All patients (n = 50)	2 (4.0)	2 (11.8)	0	0.111
BTT/BTC (n = 30)	2 (6.7)	2 (20.0)	0	0.103
DT (n = 20)	0	0	0	-
Any stroke				
All patients (n = 50)	16 (32.0)	4 (23.5)	12 (36.4)	0.357
BTT/BTC (n = 30)	9 (30.0)	2 (20.0)	7 (35.0)	0.675
DT (n = 20)	7 (35.0)	2 (28.6)	5 (38.5)	1.000
Ischemic stroke				
All patients (n = 50)	8 (16.0)	2 (11.8)	6 (18.2)	0.699
BTT/BTC (n = 30)	4 (13.3)	1 (10.0)	3 (15.0)	1.000
DT (n = 20)	4 (20.0)	1 (14.3)	3 (23.1)	1.000
Hemorrhagic stroke				
All patients (n = 50)	9 (18.0)	3 (17.6)	6 (18.2)	1.000
BTT/BTC (n = 30)	5 (16.7)	1 (10.0)	4 (20.0)	0.640
DT (n = 20)	4 (20.0)	2 (28.6)	2 (15.4)	0.587
Major bleeding				
All patients (n = 50)	26 (52.0)	9 (52.9)	17 (51.5)	0.924
BTT/BTC (n = 30)	17 (56.7)	5 (50.0)	12 (60.0)	0.705
DT (n = 20)	9 (45.0)	4 (57.1)	5 (38.5)	0.642
Bleeding requiring surgery				
All patients (n = 50)	7 (14.0)	4 (23.5)	3 (9.1)	0.210
BTT/BTC (n = 30)	4 (13.3)	2 (20.0)	2 (10.0)	0.584
DT (n = 20)	3 (15.0)	2 (28.6)	1 (7.7)	0.270
Gastrointestinal bleeding				
All patients (n = 50)	13 (26.0)	3 (17.6)	10 (30.3)	0.499
BTT/BTC (n = 30)	5 (23.3)	1 (10.0)	6 (30.0)	0.372
DT (n = 20)	6 (30.0)	2 (28.6)	4 (30.8)	1.000

Values are presented as number (%).

HVAD, HeartWare Ventricular Assist Device; BTT/BTC, bridge to transplantation/bridge to candidacy; DT, destination therapy.